Clinical Trials on Uterine Myomas, Leiomyomas, or Fibromas in Norway

Total 34 results

Philips Healthcare
Philips Medical Systems

Completed

Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI Scanner

Uterine Leiomyomas

Norway
Oslo University Hospital

Unknown

Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy

Dysmenorrhea | Total Laparoscopic Hysterectomy | Abnormal Uterine Bleeding | Laparoscopic Supracervical Hysterectomy | Fibromas

Norway
Ullevaal University Hospital

Unknown

Hysteroscopic Monopolar and Bipolar Resection

Polyps | Menorrhagia | Fibroid

Norway
Ethicon, Inc.

Terminated

A Pilot Study to Determine Optimal Procedure Steps to Obtain and Maintain Uterine Artery Occlusion With the D-UAO Device

Uterine Fibroids

Austria, Germany, Netherlands, Norway
Ullevaal University Hospital

Unknown

Laparoscopic Occlusion of Uterine Vessels Compared to Uterine Fibroid Embolization for Treatment of Uterine Fibroids

Uterine Fibroids

Norway
Oslo University Hospital

Recruiting

Fibroids and Infertility - a Study of the Significance of Removal of Fibroids With Regard to Endometrial Receptivity (FIN)

Leiomyoma, Uterine

Norway
Ethicon, Inc.

Terminated

Uterine Artery Occlusion for Fibroid Related Bleeding

Uterine Fibroids | Menorrhagia

Netherlands, Denmark, France, Germany, Norway, Switzerland, United Kingdom
Myovant Sciences GmbH

Completed

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroids | Uterine Leiomyoma

United States, Italy, Poland, Czechia, Hungary, South Africa, Brazil, Chile
Bayer

Terminated

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 5)

Uterine Fibroids

Spain, Korea, Republic of, Denmark, Taiwan, Hungary, Lithuania, Austria, Portugal, Germany, Australia, Canada, Sweden, Bulgaria, Czechia, Finland, Norway, Poland, United Kingdom, Belgium, Italy, Slovakia, Netherlands, Ireland
Bayer

Active, not recruiting

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 6)

Uterine Fibroids

United States, China, Thailand, Japan, Turkey, Czechia, Finland, Hong Kong, Mexico, Norway, Poland, Russian Federation, South Africa
Myovant Sciences GmbH

Completed

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Italy, Poland, Brazil, South Africa, United Kingdom
AbbVie

Completed

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada, Puerto Rico
AbbVie

Completed

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

Uterine Fibroids | Heavy Menstrual Bleeding

United States, Canada
Bayer

Completed

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids (ASTEROID 2)

Leiomyoma

Spain, Portugal, Netherlands, Austria, Germany, Hungary, Belgium, Bulgaria, Finland, United Kingdom, Sweden, Poland, Italy, Czech Republic, Lithuania, Norway
Oslo University Hospital

Recruiting

Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis

Cystic Fibrosis in Children

Norway
Oslo University Hospital

Completed

Pre-flight Evaluation of Adult Patients With Cystic Fibrosis

Cystic Fibrosis

Norway
Haukeland University Hospital

Completed

High Volumes of Hypertonic Saline and Chest Physiotherapy in CF Patients

Cystic Fibrosis

Norway
Haukeland University Hospital
University of Bergen

Unknown

Exocrine Pancreatic Function Testing in Cystic Fibrosis

Cystic Fibrosis

Norway
Oslo University Hospital
University Hospital, Akershus; The Norwegian Resouce Centre for Cystic Fibrosis and other collaborators

Completed

Cystic Fibrosis and Fit-to-Fly (CyFF)

Lung Diseases | Cystic Fibrosis | Hypoxemia

Norway
Myovant Sciences GmbH

Completed

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Uterine Fibroid | Heavy Menstrual Bleeding

United States, Italy, Belgium, Czechia, Hungary, Poland, South Africa, Chile, Brazil
Karolinska Institutet
European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Enrolling by invitation

NETwork of Linoleic Acid Supplementation in Cystic Fibrosis (NETLACF)

Cystic Fibrosis

Poland, Italy, Norway, Sweden
Rigshospitalet, Denmark
Cystic Fibrosis Foundation

Completed

Scandinavian Cystic Fibrosis Azithromycin Study

Cystic Fibrosis

Denmark, Norway, Sweden
Oslo University Hospital
Merck Sharp & Dohme LLC

Terminated

A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery

Malignant Peripheral Nerve Sheath Tumour (MPNST)

Norway
AlgiPharma AS
Eurostars; Smerud Medical Research International AS

Completed

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984)

Cystic Fibrosis

United Kingdom, Denmark, Norway, Germany, Sweden
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
Symbollon Pharmaceuticals

Unknown

Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain

Pain | Fibrocystic Disease of Breast | Fibrocystic Changes of Breast | Fibrocystic Mastopathy

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma and other conditions

United States

Clinical Trials on Uterine Myomas, Leiomyomas, or Fibromas in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations